[pending] XYLOCAINE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE)
Pending LLM rewrite. Source: FDA_DRUG D-0228-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Defective container: cracked/broken cartridges
The recalled product
- Product
- XYLOCAINE (LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE)
- Brand
- XYLOCAINE
- Manufacturer
- Novocol Pharmaceutical of Canada, Inc.
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: D05337B
- expires: 06-30-2027
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · XYLOCAINE
- HighXylocaine Lidocaine Injectable Anesthetic Recalled for Storage Temperature Abuse
FDA (Drugs) · 2022-06-15
- HighXylocaine injectable anesthetic recalled for temperature abuse during manufacturing
FDA (Drugs) · 2022-06-15
- ModerateXylocaine Lidocaine Injection Recalled for Low Epinephrine Assay Results
FDA (Drugs) · 2021-07-14
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereMG217 Multi-Symptom Treatment Cream recalled for microbial contamination
FDA (Drugs) · 2026-05-27